Company / Accounts Receivable
Crinetics Pharmaceuticals, Inc. Accounts Receivable History
FY2025-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$592.0K
FY2025
5-year range
$592.0K / $592.0K
FY2025-FY2025
Trend
-
vs FY2024
Sector context
#109 of 113
Health Care
What the data says
Among 113 Health Care companies, Crinetics Pharmaceuticals, Inc. is in the bottom 4% for accounts receivable.
Based on SEC 10-K filings.
$592,000 in FY2025.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 113This company $592.0K Sector average $1.1B
▼
-99.9% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $592.0K | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026